Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1 Million AUD | 69.6% |
| 2023 | -3.31 Million AUD | 66.51% |
| 2022 | -9.9 Million AUD | -47.27% |
| 2021 | -6.72 Million AUD | -12.96% |
| 2020 | -5.95 Million AUD | -8.72% |
| 2019 | -5.47 Million AUD | -8504.73% |
| 2018 | -63.65 Thousand AUD | -150.84% |
| 2017 | 125.19 Thousand AUD | 102.62% |
| 2016 | -4.77 Million AUD | -129.6% |
| 2015 | -2.07 Million AUD | 21.53% |
| 2014 | -2.65 Million AUD | 18.29% |
| 2013 | -3.24 Million AUD | 0.0% |
| 2010 | -8.42 Million AUD | 41.5% |
| 2009 | -14.4 Million AUD | -118.35% |
| 2008 | -6.59 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -202.72 Thousand AUD | 61.25% |
| 2024 FY | -1 Million AUD | 69.6% |
| 2024 Q4 | -541.63 Thousand AUD | 0.0% |
| 2024 Q2 | -467.12 Thousand AUD | -130.42% |
| 2023 Q1 | -782.96 Thousand AUD | 91.59% |
| 2023 FY | -3.31 Million AUD | 66.51% |
| 2023 Q4 | -523.19 Thousand AUD | -167.61% |
| 2023 Q3 | -195.5 Thousand AUD | 93.3% |
| 2023 Q2 | -2.91 Million AUD | -272.75% |
| 2022 FY | -9.9 Million AUD | -47.27% |
| 2022 Q3 | -2.92 Million AUD | 54.42% |
| 2022 Q4 | -9.3 Million AUD | -218.61% |
| 2022 Q2 | -6.4 Million AUD | -215.49% |
| 2022 Q1 | -2.03 Million AUD | 69.74% |
| 2021 Q4 | -6.71 Million AUD | -221.38% |
| 2021 Q1 | -1.36 Million AUD | 53.92% |
| 2021 FY | -6.72 Million AUD | -12.96% |
| 2021 Q2 | -4.27 Million AUD | -213.33% |
| 2021 Q3 | -2.08 Million AUD | 51.17% |
| 2020 Q2 | -3.05 Million AUD | -256.19% |
| 2020 Q3 | -948.71 Thousand AUD | 68.92% |
| 2020 Q4 | -2.96 Million AUD | -212.23% |
| 2020 FY | -5.95 Million AUD | -8.72% |
| 2020 Q1 | -856.93 Thousand AUD | 72.16% |
| 2019 Q3 | -972.89 Thousand AUD | -100.84% |
| 2019 Q1 | -484.41 Thousand AUD | 1.35% |
| 2019 FY | -5.47 Million AUD | -8504.73% |
| 2019 Q2 | -484.41 Thousand AUD | 0.0% |
| 2019 Q4 | -3.07 Million AUD | -216.33% |
| 2018 Q2 | -432.01 Thousand AUD | 0.0% |
| 2018 Q1 | -432.01 Thousand AUD | -2.7% |
| 2018 FY | -63.65 Thousand AUD | -150.84% |
| 2018 Q4 | -491.05 Thousand AUD | 0.0% |
| 2018 Q3 | -491.05 Thousand AUD | -13.67% |
| 2017 Q2 | -454.03 Thousand AUD | 0.0% |
| 2017 Q4 | -420.64 Thousand AUD | 0.0% |
| 2017 Q3 | -420.64 Thousand AUD | 7.35% |
| 2017 FY | 125.19 Thousand AUD | 102.62% |
| 2017 Q1 | -454.03 Thousand AUD | 19.32% |
| 2016 Q2 | -466.82 Thousand AUD | 0.0% |
| 2016 FY | -4.77 Million AUD | -129.6% |
| 2016 Q1 | -466.82 Thousand AUD | -81.09% |
| 2016 Q4 | -562.78 Thousand AUD | 0.0% |
| 2016 Q3 | -562.78 Thousand AUD | -20.56% |
| 2015 Q2 | -782.2 Thousand AUD | 0.0% |
| 2015 Q1 | -782.2 Thousand AUD | -36.52% |
| 2015 FY | -2.07 Million AUD | 21.53% |
| 2015 Q4 | -257.78 Thousand AUD | 0.0% |
| 2015 Q3 | -257.78 Thousand AUD | 67.04% |
| 2014 Q4 | -572.95 Thousand AUD | 0.0% |
| 2014 Q3 | -572.95 Thousand AUD | 23.84% |
| 2014 Q2 | -752.3 Thousand AUD | 0.0% |
| 2014 Q1 | -752.3 Thousand AUD | -4.98% |
| 2014 FY | -2.65 Million AUD | 18.29% |
| 2013 Q2 | -905.38 Thousand AUD | 0.0% |
| 2013 FY | -3.24 Million AUD | 0.0% |
| 2013 Q3 | -716.61 Thousand AUD | 20.85% |
| 2013 Q1 | -905.38 Thousand AUD | 0.0% |
| 2013 Q4 | -716.61 Thousand AUD | 0.0% |
| 2010 FY | -8.42 Million AUD | 41.5% |
| 2009 FY | -14.4 Million AUD | -118.35% |
| 2008 FY | -6.59 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 110.382% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 30.866% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 83.013% |
| Biome Australia Limited | -1.91 Million AUD | 47.275% |
| Patrys Limited | -3.53 Million AUD | 71.497% |
| Orthocell Limited | -11.68 Million AUD | 91.364% |
| Imugene Limited | -140.93 Million AUD | 99.284% |
| Noxopharm Limited | -7.53 Million AUD | 86.612% |
| PYC Therapeutics Limited | -38.85 Million AUD | 97.404% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 91.805% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 85.963% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 86.051% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 88.547% |
| CSL Limited | 5.64 Billion AUD | 100.018% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 85.976% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 67.061% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 102.052% |
| Starpharma Holdings Limited | -15.15 Million AUD | 93.346% |
| Nanollose Limited | -1.24 Million AUD | 19.289% |
| Memphasys Limited | -2.7 Million AUD | 62.694% |
| Invex Therapeutics Ltd | -2.13 Million AUD | 52.721% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | 50.95% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 77.203% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 93.138% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 64.898% |
| Race Oncology Limited | -13.38 Million AUD | 92.461% |
| Nyrada Inc. | -4.56 Million AUD | 77.88% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 95.975% |
| PharmAust Limited | -6.65 Million AUD | 84.85% |
| Immutep Limited | -44.93 Million AUD | 97.755% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 97.748% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 94.854% |
| BTC Health Limited | 1.05 Million AUD | 195.59% |
| Acrux Limited | -9.83 Million AUD | 89.742% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 100.446% |
| Biotron Limited | -5.15 Million AUD | 80.417% |
| Tissue Repair Ltd | -4.87 Million AUD | 79.312% |
| AdAlta Limited | -5.26 Million AUD | 80.828% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 97.863% |
| AnteoTech Limited | -11.72 Million AUD | 91.398% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 98.451% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 95.425% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 78.019% |
| Actinogen Medical Limited | -12.83 Million AUD | 92.143% |
| Immuron Limited | -5.8 Million AUD | 82.611% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 82.213% |